Translational Psychiatry
July 20, 2026
Yong-Yu Yin, Si-Rui Sun, Hui-Ying Zhang et al.
Ketamine, a non-competitive N-methyl-D-aspartate acid (NMDA) receptor antagonist, produces rapid and sustained antidepressant actions, but the underlying molecular mechanism remains unclear. The CX 3 CL1/CX 3 CR1 signaling is closely related to mood disorders, and this study aims to investigate its role in ketamine’s antidepressant actions. We pharmacologically (AZD8797, a selective CX 3 CR1...
Progress in Neuro-psychopharmacology and Biological Psychiatry
April 1, 2026
Yong-xing Qiao, Wei Dai, Yi-shan Yao et al.
1 citation
Psilocybin showed a rapid antidepressant response in several clinical trials, which offers new hope for treating depression. Astrocytes were associated with the etiology of depression and might contribute to the onset of psilocybin. In this study, we investigated the fast antidepressant effect of psilocybin and tested variations of GFAP (astrocytic markers) and C3 protein (markers of A1...
British Journal of Pharmacology
December 1, 2024
Yong-Yu Yin, Jiao-Zhao Yan, Qian-Qian Wei et al.
13 citations
The emerging antidepressant effects of ketamine have inspired tremendous interest in its underlying neurobiological mechanisms, although the involvement of 5-HT in the antidepressant effects of ketamine remains unclear. The chronic restraint stress procedure was performed to induce depression-like behaviours in mice. OFT, FST, TST, and NSFT tests were used to evaluate the antidepressant-like...
Journal of Psychopharmacology
April 28, 2024
Xiangting Zhao, Yingjie Du, Yishan Yao et al.
53 citations
Background: Psilocybin offers new hope for treating mood disorders due to its rapid and sustained antidepressant effects, as standard medications require weeks or months to exert their effects. However, the mechanisms underlying this action of psilocybin have not been identified. Aims: To investigate whether psilocybin has rapid and sustained antidepressant-like effects in mice and investigate...